|
1
|
Li X, He S and Ma B: Autophagy and
autophagy-related proteins in cancer. Mol Cancer. 19:122020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ieni A, Cardia R, Giuffrè G, Rigoli L,
Caruso RA and Tuccari G: Immunohistochemical expression of
autophagy-related proteins in advanced tubular gastric
adenocarcinomas and its implications. Cancers (Basel). 11:3892019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Broggi G, Ieni A, Russo D, Varricchio S,
Puzzo L, Russo A, Reibaldi M, Longo A, Tuccari G, Staibano S and
Caltabiano R: The macro-autophagy-related protein beclin-1
immunohistochemical expression correlates with tumor cell type and
clinical behavior of uveal melanoma. Front Oncol. 10:5898492020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ieni A, Pizzimenti C, Giuffrè G, Caruso RA
and Tuccari G: Autophagy-related prognostic signature in HER2
positive gastric carcinomas. Curr Mol Med. 22:809–818. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eskelinen EL: The dual role of autophagy
in cancer. Curr Opin Pharmacol. 11:294–300. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chmurska A, Matczak K and Marczak A: Two
faces of autophagy in the struggle against cancer. Int J Mol Sci.
22:29812021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Verma AK, Bharti PS, Rafat S, Bhatt D,
Goyal Y, Pandey KK, Ranjan S, Almatroodi SA, Alsahli MA, Rahmani
AH, et al: Autophagy paradox of cancer: Role, regulation, and
duality. Oxid Med Cell Longev. 2021:88325412021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gerada C and Ryan KM: Autophagy, the
innate immune response and cancer. Mol Oncol. 14:1913–1929. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yun CW, Jeon J, Go G, Lee JH and Lee SH:
The dual role of autophagy in cancer development and a therapeutic
strategy for cancer by targeting autophagy. Int J Mol Sci.
22:1792020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amaravadi RK, Kimmelman AC and Debnath J:
Targeting autophagy in cancer: Recent advances and future
directions. Cancer Discov. 9:1167–1181. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang CW and Klionsky DJ: The molecular
mechanism of autophagy. Mol Med. 9:65–76. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mizushimaa N and Komatsu M: Autophagy:
Renovation of cells and tissues. Cell1. 147:728–741. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Feng Y and Klionsky DJ: Autophagy
regulates DNA repair through SQSTM1/p62. Autophagy. 13:995–996.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Metur SP and Klionsky DJ: Autophagy under
construction: Insights from in vitro reconstitution of
autophagosome nucleation. Autophagy. 17:383–384. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Deng D, Luo K, Liu H, Nie X, Xue L, Wang
R, Xu Y, Cui J, Shao N and Zhi F: p62 acts as an oncogene and is
targeted by miR-124-3p in glioma. Cancer Cell Int. 19:2802019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chao X, Ni HM and Ding W: An unexpected
tumor suppressor role of SQSTM1/p62 in liver tumorigenesis.
Autophagy. 18:459–461. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang J, Li Y, Xia S, Li J, Yang Q, Ding K
and Zhang H: Sequestosome 1/p62: A multitasker in the regulation of
malignant tumor aggression (Review). Int J Oncol. 59:772021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li D, He C, Ye F, Ye E, He H, Chen G and
Zhang J: p62 overexpression promotes bone metastasis of lung
adenocarcinoma out of LC3-dependent autophagy. Front Oncol.
11:6095482021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thongchot S, Vidoni C, Ferraresi A,
Loilome W, Khuntikeo N, Sangkhamanon S, Titapun A, Isidoro C and
Namwat N: Cancer-associated fibroblast-derived IL-6 determines
unfavorable prognosis in cholangiocarcinoma by affecting
autophagy-associated chemoresponse. Cancers (Basel). 13:21342021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Umemura A, He F, Taniguchi K, Nakagawa H,
Yamachika S, Font-Burgada J, Zhong Z, Subramaniam S, Raghunandan S,
Duran A, et al: p62, upregulated during preneoplasia, induces
hepatocellular carcinogenesis by maintaining survival of stressed
HCC-initiating cells. Cancer Cell. 29:935–948. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim JW, Jun SY, Kim JM, Oh YH, Yoon G,
Hong SM and Chung JY: Prognostic value of LC3B and p62 expression
in small intestinal adenocarcinoma. J Clin Med. 10:53982021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim HM and Koo JS: Autophagy-related
proteins are differentially expressed in adrenal cortical
tumor/pheochromocytoma and associated with patient prognosis. Int J
Mol Sci. 22:104902021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Perng DS, Hung CM, Lin HY, Morgan P, Hsu
YC, Wu TC, Hsieh PM, Yeh JH, Hsiao P, Lee CY, et al: Role of
autophagy-related protein in the prognosis of combined
hepatocellular carcinoma and cholangiocarcinoma after surgical
resection. BMC Cancer. 21:8282021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haack TB, Ignatius E, Calvo-Garrido J,
Iuso A, Isohanni P, Maffezzini C, Lönnqvist T, Suomalainen A, Gorza
M, Kremer LS, et al: Absence of the autophagy adaptor SQSTM1/p62
causes childhood-onset neurodegeneration with ataxia, dystonia, and
gaze palsy. Am J Hum Genet. 99:735–743. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Muto V, Flex E, Kupchinsky Z, Primiano G,
Galehdari H, Dehghani M, Cecchetti S, Carpentieri G, Rizza T,
Mazaheri N, et al: Biallelic SQSTM1 mutations in early-onset,
variably progressive neurodegeneration. Neurology. 91:e319–e330.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pytte J, Anderton RS, Flynn LL, Theunissen
F, Jiang L, Pitout I, James I, Mastaglia FL, Saunders AM, Bedlack
R, et al: Association of a structural variant within the SQSTM1
gene with amyotrophic lateral sclerosis. Neurol Genet. 6:e4062020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Seibenhener ML, Du Y, Diaz-Meco MT, Moscat
J, Wooten MC and Wooten MW: A role for sequestosome 1/p62 in
mitochondrial dynamics, import and genome integrity. Biochim
Biophys Acta. 1833:452–459. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bartolome F, Esteras N, Martin-Requero A,
Boutoleau-Bretonniere C, Vercelletto M, Gabelle A, Le Ber I, Honda
T, Dinkova-Kostova AT, Hardy J, et al: Pathogenic p62/SQSTM1
mutations impair energy metabolism through limitation of
mitochondrial substrates. Sci Rep. 7:16662017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Calvo-Garrido J, Maffezzini C, Schober FA,
Clemente P, Uhlin E, Kele M, Stranneheim H, Lesko N, Bruhn H,
Svenningsson P, et al: SQSTM1/p62-directed metabolic reprogramming
is essential for normal neurodifferentiation. Stem Cell Reports.
12:696–711. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Poon A, Saini H, Sethi S, O'Sullivan GA,
Plun-Favreau H, Wray S, Dawson LA and McCarthy JM: The role of
SQSTM1 (p62) in mitochondrial function and clearance in human
cortical neurons. Stem Cell Reports. 16:1276–1289. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Galavotti S, Bartesaghi S, Faccenda D,
Shaked-Rabi M, Sanzone S, McEvoy A, Dinsdale D, Condorelli F,
Brandner S, Campanella M, et al: The autophagy-associated factors
DRAM1 and p62 regulate cell migration and invasion in glioblastoma
stem cells. Oncogene. 32:699–712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chang YL, Li YF, Chou CH, Huang LC, Wu YP,
Kao Y and Tsai CK: Diosmin inhibits glioblastoma growth through
inhibition of autophagic flux. Int J Mol Sci. 22:104532021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang T and Wu Z: Immunohistochemical
assessment of autophagic protein LC3B and p62 levels in glioma
patients. Int J Clin Exp Pathol. 11:862–868. 2018.PubMed/NCBI
|
|
34
|
Tamrakar S, Yashiro M, Kawashima T, Uda T,
Terakawa Y, Kuwae Y, Ohsawa M and Ohata K: Clinicopathological
significance of autophagy-related proteins and its association with
genetic alterations in gliomas. Anticancer Res. 39:1233–1242. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ostrom QT, Adel Fahmideh M, Cote DJ,
Muskens IS, Schraw JM, Scheurer ME and Bondy ML: Risk factors for
childhood and adult primary brain tumors. Neuro Oncol.
21:1357–1375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ostrom QT, Truitt G, Gittleman H, Brat DJ,
Kruchko C, Wilson R and Barnholtz-Sloan JS: Relative survival after
diagnosis with a primary brain or other central nervous system
tumor in the national program of cancer registries, 2004 to 2014.
Neurooncol Pract. 7:306–312. 2020.PubMed/NCBI
|
|
37
|
Wen PY, Rodon JA, Mason W, Beck JT,
DeGroot J, Donnet V, Mills D, El-Hashimy M and Rosenthal M: Phase
I, open-label, multicentre study of buparlisib in combination with
temozolomide or with concomitant radiation therapy and temozolomide
in patients with newly diagnosed glioblastoma. ESMO Open.
5:e0006732020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Seyve A, Lozano-Sanchez F, Thomas A,
Mathon B, Tran S, Mokhtari K, Giry M, Marie Y, Capelle L, Peyre M,
et al: Initial surgical resection and long time to occurrence from
initial diagnosis are independent prognostic factors in resected
recurrent IDH wild-type glioblastoma. Clin Neurol Neurosurg.
196:1060062020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Le Rhun E and Weller M: Sex-specific
aspects of epidemiology, molecular genetics and outcome: Primary
brain tumours. ESMO Open. 5 (Suppl 4):e0010342020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Birzu C, French P, Caccese M, Cerretti G,
Idbaih A, Zagonel V and Lombardi G: Recurrent glioblastoma: From
molecular landscape to new treatment perspectives. Cancers (Basel).
13:472020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Brandes AA, Franceschi E, Tosoni A,
Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A,
Skrap M, et al: O(6)-methylguanine DNA-methyltransferase
methylation status can change between first surgery for newly
diagnosed glioblastoma and second surgery for recurrence: Clinical
implications. Neuro Oncol. 12:283–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brandes AA, Franceschi E, Paccapelo A,
Tallini G, De Biase D, Ghimenton C, Danieli D, Zunarelli E, Lanza
G, Silini EM, et al: Role of MGMT methylation status at time of
diagnosis and recurrence for patients with glioblastoma: Clinical
implications. Oncologist. 22:432–437. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Storey K, Leder K, Hawkins-Daarud A,
Swanson K, Ahmed AU, Rockne RC and Foo J: Glioblastoma recurrence
and the role of O6-methylguanine-DNA methyltransferase
promoter methylation. JCO Clin Cancer Inform. 3:1–12. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Felsberg J, Thon N, Eigenbrod S, Hentschel
B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Löffler
M, et al: Promoter methylation and expression of MGMT and the DNA
mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary
and recurrent glioblastomas. Int J Cancer. 129:659–670. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Álvarez-Torres MDM, Fuster-García E,
Balaña C, Puig J and García-Gómez JM: Lack of benefit of extending
temozolomide treatment in patients with high vascular glioblastoma
with methylated MGMT. Cancers (Basel). 13:54202021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Brigliadori G, Foca F, Dall'Agata M,
Rengucci C, Melegari E, Cerasoli S, Amadori D, Calistri D and Faedi
M: Defining the cutoff value of MGMT gene promoter methylation and
its predictive capacity in glioblastoma. J Neurooncol. 128:333–339.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ieni A, Barresi V, Caltabiano R, Caleo A,
Bonetti LR, Lanzafame S, Zeppa P, Caruso RA and Tuccari G:
Discordance rate of HER2 status in primary gastric carcinomas and
synchronous lymph node metastases: A multicenter retrospective
analysis. Int J Mol Sci. 15:22331–22341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ieni A, Barresi V, Caltabiano R, Cascone
AM, Del Sordo R, Cabibi D, Zeppa P, Lanzafame S, Sidoni A, Franco V
and Tuccari G: Discordance rate of HER2 status in primary breast
carcinomas versus synchronous axillary lymph node metastases: A
multicenter retrospective investigation. Onco Targets Ther.
7:1267–1272. 2014.PubMed/NCBI
|
|
49
|
Ieni A, Cardia R, Pizzimenti C, Zeppa P
and Tuccari G: HER2 heterogeneity in personalized therapy of
gastro-oesophageal malignancies: An overview by different
methodologies. J Pers Med. 10:102020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zeng RX, Zhang YB, Fan Y and Wu GL:
p62/SQSTM1 is involved in caspase-8 associated cell death induced
by proteasome inhibitor MG132 in U87MG cells. Cell Biol Int.
38:1221–1226. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ivankovic D, Chau KY, Schapira AH and Gegg
ME: Mitochondrial and lysosomal biogenesis are activated following
PINK1/parkin-mediated mitophagy. J Neurochem. 136:388–402. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Śledzińska P, Bebyn MG, Furtak J,
Kowalewski J and Lewandowska MA: Prognostic and predictive
biomarkers in gliomas. Int J Mol Sci. 22:103732021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Brandner S, McAleenan A, Kelly C, Spiga F,
Cheng HY, Dawson S, Schmidt L, Faulkner CL, Wragg C, Jefferies S,
et al: MGMT promoter methylation testing to predict overall
survival in people with glioblastoma treated with temozolomide: A
comprehensive meta-analysis based on a cochrane systematic review.
Neuro Oncol. 23:1457–1469. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Broggi G, Salvatorelli L, Barbagallo D,
Certo F, Altieri R, Tirrò E, Massimino M, Vigneri P, Guadagno E,
Maugeri G, et al: Diagnostic utility of the immunohistochemical
expression of serine and arginine rich splicing factor 1 (SRSF1) in
the differential diagnosis of adult gliomas. Cancers (Basel).
13:20862021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Certo F, Altieri R, Maione M, Schonauer C,
Sortino G, Fiumanò G, Tirrò E, Massimino M, Broggi G, Vigneri P, et
al: FLAIRectomy in supramarginal resection of glioblastoma
correlates with clinical outcome and survival analysis: A
prospective, single institution, case series. Oper Neurosurg
(Hagerstown). 20:151–163. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Stella M, Falzone L, Caponnetto A, Gattuso
G, Barbagallo C, Battaglia R, Mirabella F, Broggi G, Altieri R,
Certo F, et al: Serum extracellular vesicle-derived circHIPK3 and
circSMARCA5 Are two novel diagnostic biomarkers for glioblastoma
multiforme. Pharmaceuticals (Basel). 14:6182021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang QW, Liu HJ, Zhao Z, Zhang Y, Wang Z,
Jiang T and Bao ZS: Prognostic correlation of autophagy-related
gene expression-based risk signature in patients with glioblastoma.
Onco Targets Ther. 13:95–107. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Khan I, Baig MH, Mahfooz S, Rahim M,
Karacam B, Elbasan EB, Ulasov I, Dong JJ and Hatiboglu MA:
Deciphering the role of autophagy in treatment of resistance
mechanisms in glioblastoma. Int J Mol Sci. 22:13182021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Batara DCR, Choi MC, Shin HU, Kim H and
Kim SH: Friend or foe: Paradoxical roles of autophagy in
gliomagenesis. Cells. 10:14112021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Shukla S, Patric IR, Patil V, Shwetha SD,
Hegde AS, Chandramouli BA, Arivazhagan A, Santosh V and
Somasundaram K: Methylation silencing of ULK2, an autophagy gene,
is essential for astrocyte transformation and tumor growth. J Biol
Chem. 289:22306–22318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Miracco C, Cosci E, Oliveri G, Luzi P,
Pacenti L, Monciatti I, Mannucci S, De Nisi MC, Toscano M,
Malagnino V, et al: Protein and mRNA expression of autophagy gene
beclin 1 in human brain tumours. Int J Oncol. 30:429–436.
2007.PubMed/NCBI
|
|
62
|
Aoki H, Kondo Y, Aldape K, Yamamoto A,
Iwado E, Yokoyama T, Hollingsworth EF, Kobayashi R, Hess K,
Shinojima N, et al: Monitoring autophagy in glioblastoma with
antibody against isoform B of human microtubule-associated protein
1 light chain 3. Autophagy. 4:467–475. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Mecca C, Giambanco I, Donato R and Arcuri
C: Targeting mTOR in glioblastoma: Rationale and
preclinical/clinical evidence. Dis Markers. 2018:92304792018.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Li XY, Zhang LQ, Zhang XG, Li X, Ren YB,
Ma XY, Li XG and Wang LX: Association between AKT/mTOR signalling
pathway and malignancy grade of human gliomas. J Neurooncol.
103:453–458. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jhanwar-Uniyal M, Jeevan D, Neil J,
Shannon C, Albert L and Murali R: Deconstructing mTOR complexes in
regulation of glioblastoma multiforme and its stem cells. Adv Biol
Regul. 53:202–210. 2013. View Article : Google Scholar : PubMed/NCBI
|
